New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients.
Therapies aimed at inhibiting tumor necrosis factor, a proinflammatory cytokine implicated in autoimmune disease, are effective for rheumatoid arthritis (RA) and Crohn's disease. We report two patients who newly developed multiple demyelinating lesions in the central nervous system in the course of infliximab therapy for active RA. Neurological symptoms and the number of gadolinium-diethylenetriamine pentaacetic acid-enhanced lesions in magnetic resonance imaging gradually diminished with steroid treatment.
Tanno
Makoto
M
Department of Rheumatology, Yugawara Kosei-Nenkin Hospital, 438 Miyakami, Yugawara, Ashigara-shimo, Kanagawa, 259-0314, Japan.
Nakamura
Ichiro
I
Kobayashi
Shunsuke
S
Kurihara
Kumiko
K
Ito
Katsumi
K
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002493:Central Nervous System Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D003287:Contrast Media; D003711:Demyelinating Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D019786:Gadolinium DTPA; D006801:Humans; D000069285:Infliximab; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D013256:Steroids / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D003287:Contrast Media; D013256:Steroids; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D019786:Gadolinium DTPA